This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

The collection offers a glimpse into differences in cell composition — across people and brain regions — that may shape neural function.

Alterations in inhibitory circuits and difficulties in social recognition characterize mice missing one copy of DYRK1A, a gene linked to autism.

After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

The inhibitory cells misfire and contribute to social difficulties in mice that model the syndrome.

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.

In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.